Enzyme Produced in the Liver Can Treat Fatty Liver Disease

DPP4 inhibitors are usually given for type 2 diabetes. These inhibitors not only improve the sugar metabolism, but can also treat non-alcoholic fatty liver disease.

Increased production of the enzyme DPP4 by the liver promotes an increase in body fat, the development of non-alcoholic fatty liver disease and insulin resistance, reveals a new study. //

"In combination with our observations from additional human and cell studies, these results indicate that increased DPP4 production by the liver is the cause rather than the consequence of a fatty liver and insulin resistance," says the head of the study, Annette Schürmann from the German Institute for Human Nutrition Research (DIfE), a partner of the German Center for Diabetes Research (DZD).

‘DPP4 enzyme produced in the liver promotes obesity, non-alcoholic fatty liver disease, and insulin resistance.’

The research team led by Schürmann published its findings in Molecular Metabolism. These were the findings of a current study by DZD-researchers in Potsdam and Tübingen. //

"DPP4 inhibitors are well known from the treatment of diabetes. Therefore, in our opinion, they could be used in the future not only to improve the sugar metabolism but also to treat non-alcoholic fatty liver disease," adds the lead author of the study, Christian Baumeier from DIfE.

DPP4 is an enzyme that, to a large extent, is produced by the liver and inhibits the effects of important intestinal hormones that are involved in blood glucose metabolism.

Fibroscan for Fatty Liver Cirrhosis and Fibrosis - Causes, Symptoms, Treatment
Recently, Fibroscan has incorporated the noninvasive Controlled Attenuation Parameter technique to estimate the degree of fatty infiltration in the liver.

In addition, patients suffering from non-alcoholic fatty liver disease have elevated DPP4 levels in their blood. To date, however, it was unclear whether elevated levels of DPP4 in fatty livers are the cause or consequence of the disease.

In order to find an answer to this question, scientists working with Schürmann and Baumeier compared two different groups of mice with each other. While one group of mice produced an increased amount of DPP4 in the liver due to a genetic modification, the control group showed low amounts of the enzyme.

Alcoholic Liver Disease - Causes Symptoms Diagnosis Treatment FAQs
Encyclopedia section of medindia gives general information about Alcoholic Liver Disease.

Both groups were given the same high-fat feed for approx. half a year. The animals that produced an increased amount of DPP4 in the liver gained about one-third more body fat than the control group and showed about twice as much liver fat. They also reacted less sensitive to the hormone insulin.

Additional studies on a human liver cell line as well as on isolated liver cells of the mice also indicated that normal amounts of DPP4 (500ng/ml) are already sufficient to make the cells less sensitive to insulin regardless of their fat content.

Fatty Liver Disease: A Growing Health Problem in India - Causes, Symptoms, Diagnosis, Treatment
Non alcoholic fatty liver disease (NAFLD) is the leading cause of liver dysfunction worldwide and is a rapidly growing health problem in India.

In addition, the scientists observed that human beings suffering from insulin resistance and non-alcoholic fatty liver disease have a greater amount of active DPP4 in their blood than healthy people.

"From other studies we know that epigenetic modifications of the DPP4 gene, which are associated with an increased production of the enzyme, have a negative impact on the liver metabolism already in young mice, long before fatty liver disease emerges," says Baumeier. "It therefore seems reasonable to examine in further studies how and at what time DPP4 inhibitors can be used to prevent or to treat the development of a non-alcoholic fatty liver," added Schürmann, who heads the Department of Experimental Diabetology at the DIfE.

Source-Eurekalert